- Home
- PFLT vs CDTX Comparison
PFLT vs CDTX Comparison
Compare PFLT & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- CDTX
- Stock Information
- Founded
- PFLT 2010
- CDTX 2012
- Country
- PFLT United States
- CDTX United States
- Employees
- PFLT N/A
- CDTX N/A
- Industry
- PFLT Finance: Consumer Services
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFLT Finance
- CDTX Health Care
- Exchange
- PFLT Nasdaq
- CDTX Nasdaq
- Market Cap
- PFLT 1.1B
- CDTX 980.1M
- IPO Year
- PFLT N/A
- CDTX 2015
- Fundamental
- Price
- PFLT $10.47
- CDTX $63.31
- Analyst Decision
- PFLT Buy
- CDTX Strong Buy
- Analyst Count
- PFLT 5
- CDTX 11
- Target Price
- PFLT $11.05
- CDTX $52.11
- AVG Volume (30 Days)
- PFLT 636.8K
- CDTX 659.9K
- Earning Date
- PFLT 08-11-2025
- CDTX 08-07-2025
- Dividend Yield
- PFLT 11.75%
- CDTX N/A
- EPS Growth
- PFLT N/A
- CDTX N/A
- EPS
- PFLT 0.86
- CDTX N/A
- Revenue
- PFLT $232,975,000.00
- CDTX $302,000.00
- Revenue This Year
- PFLT $45.12
- CDTX N/A
- Revenue Next Year
- PFLT $9.18
- CDTX N/A
- P/E Ratio
- PFLT $12.15
- CDTX N/A
- Revenue Growth
- PFLT 49.56
- CDTX N/A
- 52 Week Low
- PFLT $8.82
- CDTX $10.14
- 52 Week High
- PFLT $11.90
- CDTX $66.95
- Technical
- Relative Strength Index (RSI)
- PFLT 45.44
- CDTX 70.66
- Support Level
- PFLT $10.40
- CDTX $60.71
- Resistance Level
- PFLT $10.66
- CDTX $66.95
- Average True Range (ATR)
- PFLT 0.14
- CDTX 4.25
- MACD
- PFLT -0.04
- CDTX -0.39
- Stochastic Oscillator
- PFLT 13.54
- CDTX 79.25
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.